Oral PROTAC Degrader Targets STAT6 in Atopic Dermatitis
- A new PROTAC degrader targets STAT6, the transcription factor that carries IL-4/IL-13 signals driving Th2-type allergic inflammation.
- Instead of inhibiting STAT6, the molecule links a STAT6-binding fragment to a degradation handle for potency and selectivity over related STAT proteins.
- It reportedly showed oral efficacy in preclinical models, pointing to a pill-based alternative to injectable biologics for atopic dermatitis.
💡 Points
Oral bioavailability is the harder win here than target choice — PROTACs routinely blow past Lipinski/bRo5 limits (MW, PSA), so a gut-stable, orally efficacious degrader is the rarer synthetic feat. If STAT1/3/5 selectivity holds up in vivo, this leapfrogs injectable dupilumab and pressures other oral STAT6 degrader programs already in the clinic.